Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


14. May 2020 | 13:11 CET

BioNTech, EXMceuticals, Shop Apotheke Europe, Symrise - Shares gaining momentum

  • Health

The easing of measures to contain the Corona Pandemic will be further extended and, in parallel, companies and their employees will be able to increase personal communications again. However, the curfew phase was also used for strategic decisions and developments, as investors can see from announcements in recent weeks. The situation represents a crisis for many people, but it is also an opportunity for change and a new beginning. Market participants have learned in recent months that dependence on China leads to many bottlenecks and global diversification is therefore necessary. Anyone who wants to be part of it must have the right shares in their portfolio.

time to read: 1 minutes by Mario Hose


 

Emergence of an EU player

The former Goldman Sachs manager Jonathan Summers took over the helm at the young supplier EXMceuticals at the end of 2019. The company focuses on the production of pure ingredients and active ingredients for the healthcare sector.

Medical products have a particularly high standard and the more demanding the market, the higher the margins are usually. Last week, EXMceuticals announced the first buyer, thus attracting the attention of investors. The company is listed on the stock exchanges in Germany and Canada and the share price has already increased.

Healthcare market in transition

EXMceuticals will be established in Europe in the context of a shell acquisition in 2019. From Lisbon in Portugal, the operative business will be implemented and customers will be supplied. The main focus is on the EU. A growth market for pure ingredients extracted from the cannabis plant will gain in importance in the coming years. The European location is particularly exciting in view of the fact that in future the residence and the closeness to the market will be a competitive advantage.

Since COVID-19 at the latest, people in the EU have known how high the dependence on Asian suppliers is. Many an investor in EXMceuticals, with its current market value of around EUR 13 million, recalls the early phase of Symrise, which now has a market capitalization of EUR 13 billion.

Profits with solutions

The companies BioNTech and Shop Apotheke Europe have been among the problem solvers and bearers of hope since the spread of COVID-19 in the investor circles. The shares of these companies have risen accordingly. Shop Apotheke has been particularly in demand in recent months in the context of the supply of drugs and health-related products because of temporary supply bottlenecks in shops or because people did not dare to go out into the streets and the online shop offered an alternative source of supply.

The BioNTech shares benefited from the success reports in connection with the development of a vaccine for COVID-19. The market value of BioNTech is currently USD 11.00 billion and that of Shop Apotheke Europe EUR 1.16 billion.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

29. July 2020 | 07:29 CET

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

  • Health

The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.

Read

08. June 2020 | 11:30 CET

Aurora, Bayer, XPhyto - scalable growth markets with potential

  • Health

Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and therapies. The development of new markets and preparations usually requires a lot of risk capital before the fruits can be harvested. At the latest when a scalable solution has been found to improve people's lives, then the value of the company increases.

Read

16. April 2020 | 07:55 CET

Johnson & Johnson, Memphasys, Procter & Gamble - for a better life

  • Health

Good health is a valuable possession. Small and large companies around the globe are engaged in research and development to make people's lives easier or better through modern and innovative products and solutions. The consumer goods and pharmaceutical sectors often offer attractive opportunities for investors to generate a lucrative return. Well-known companies with established brands usually ensure lasting sales. However, promising young companies also use innovations to attract the attention of investors and customers.

Read